Senseonics Holdings, Inc. to Attend May 2024 Conferences

GERMANTOWN, Md.-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company dedicated to developing and manufacturing long-term, implantable continuous glucose monitoring (CGM) systems for individuals with diabetes, has announced its participation in two upcoming conferences in New York, NY.

The company's management will attend the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35pm ET. They will also conduct one-on-one meetings during the event. Furthermore, Senseonics' management is slated to participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 4:00pm ET, where they will also engage in individual meetings.

About Senseonics

Senseonics Holdings, Inc. is a company specializing in medical technology, focusing on creating and producing glucose monitoring devices that aim to improve the lives of those in the global diabetes community. The company's flagship product, the Eversense® E3 CGM system, features a small sensor fully implanted under the skin. This sensor works in conjunction with a smart transmitter worn over it, which continuously sends glucose data every five minutes to a mobile application on the user's smartphone.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!